(18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

BACKGROUND: Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have significantly improved survival in advanced melanoma. Biomarkers are urgently needed as a majority of patients do not respond, despite treatment-related toxicities. We analysed pre-treatment (18)F-fluor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Annie, Callahan, Jason, Keyaerts, Marleen, Neyns, Bart, Mangana, Johanna, Aberle, Susanne, Herschtal, Alan, Fullerton, Sonia, Milne, Donna, Iravani, Amir, McArthur, Grant A., Hicks, Rodney J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227105/
https://www.ncbi.nlm.nih.gov/pubmed/32408884
http://dx.doi.org/10.1186/s40644-020-00313-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227105/
https://www.ncbi.nlm.nih.gov/pubmed/32408884
http://dx.doi.org/10.1186/s40644-020-00313-2

Ejemplares similares